Public Offering Transactions

• eHi Car Services in its US$325 million Regulation S high-yield bond offering due 2027
• CICC, CCB, CMB, CMS and other underwriters in the approximately US$150 million IPO of Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) on the Hong Kong Stock Exchange
• Beauty Farm Medical and Health Industry Inc. in its approximately US$100 million IPO and listing on the Hong Kong Stock Exchange
• Yonghe Medical Group Co., Ltd. in its US$206 million IPO and listing on the Hong Kong Stock Exchange
• Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited and other underwriters in the US$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
• J.P. Morgan, BofA Securities, CICC and Haitong International as joint sponsors and other underwriters in the approximately US$1.67 billion secondary listing of GDS Holdings Limited on the Hong Kong Stock Exchange
• Keymed Biosciences Inc. in its US$398 million IPO and listing on the Hong Kong Stock Exchange
• Pharmaron in its US$600 million zero coupon convertible bonds offering
• Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
• Fortune Financial Capital as sole sponsor, Fortune Securities, CICC as joint global coordinators and other underwriters in the US$56.8 million primary listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
• Akeso Biopharma in its US$383 million IPO and listing on the Hong Kong Stock Exchange
• Viva Biotech in its US$194 million IPO on the Main Board of the Hong Kong Stock Exchange
• Hua Medicine in its US$110 million IPO on the Main Board of the Hong Kong Stock Exchange
• China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange

Mergers & Acquisitions

• Acotec Scientific in its approximately US$520 million voluntary partial offer by Boston Scientific
• China VAST Industrial Urban Development (6166.HK) and its controlling shareholder, Profit East Limited, in the US$285 million all-cash take private proposal by China Jinmao Holdings Group Limited (817.HK)
• Central China Real Estate and its Controlling Shareholder in US$83 Million Share Sale
• Viva Biotech in its US$387.3 million acquisition of Langhua Pharmaceutical and US$135.4 million share placement
• Global Infrastructure Solutions Inc. in its strategic merger with J. Roger Preston
• The controlling shareholder of Central China Real Estate (0832.HK) in acquiring the second largest shareholder's entire interest in Central China Real Estate 
• China International Marine Containers in its spin-off sale of Pteris Global Limited to its China Fire Safety Enterprise Group (0445.HK)
• An investor in the acquisition of a Hong Kong listed PRC-based construction company by way of a mandatory general offer